PSTV Plus Therapeutics Inc
Price (delayed)
$1.49
Market cap
$8.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.9
Enterprise value
$7.31M
Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform
Highlights
The EPS has surged by 63% year-on-year and by 4.6% since the previous quarter
PSTV's debt is down by 31% year-on-year and by 9% since the previous quarter
PSTV's revenue has soared by 113% YoY but it is down by 9% QoQ
Plus Therapeutics's gross profit has surged by 113% YoY but it has decreased by 9% QoQ
The equity has dropped by 58% since the previous quarter
Key stats
What are the main financial stats of PSTV
Market
Valuations
Earnings
Shares outstanding
5.9M
Market cap
$8.79M
Enterprise value
$7.31M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.33
Revenue
$5.51M
EBIT
-$9.48M
EBITDA
-$8.72M
Free cash flow
-$10.12M
Per share
Balance sheet
Liquidity
EPS
-$2.9
Free cash flow per share
-$1.56
Book value per share
-$1.34
Revenue per share
$0.85
TBVPS
$1.58
Total assets
$11.21M
Total liabilities
$18.84M
Debt
$3.43M
Equity
-$7.63M
Working capital
-$9.41M
Debt to equity
-0.45
Current ratio
0.5
Quick ratio
0.45
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-158.2%
Gross margin
100%
Net margin
-240.2%
Operating margin
-256.1%
Return on assets
-127.5%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-172%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PSTV stock price
How has the Plus Therapeutics stock price performed over time
Intraday
0.68%
1 week
22.13%
1 month
9.56%
1 year
7.19%
YTD
-14.86%
QTD
1.36%
Financial performance
How have Plus Therapeutics's revenue and profit performed over time
Revenue
$5.51M
Gross profit
$5.51M
Operating income
-$14.11M
Net income
-$13.23M
Gross margin
100%
Net margin
-240.2%
PSTV's revenue has soared by 113% YoY but it is down by 9% QoQ
Plus Therapeutics's gross profit has surged by 113% YoY but it has decreased by 9% QoQ
PSTV's net margin has surged by 64% year-on-year but it is down by 24% since the previous quarter
PSTV's operating margin has surged by 61% year-on-year but it is down by 31% since the previous quarter
Growth
What is Plus Therapeutics's growth rate over time
Valuation
What is Plus Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.33
The EPS has surged by 63% year-on-year and by 4.6% since the previous quarter
The equity has dropped by 58% since the previous quarter
PSTV's revenue has soared by 113% YoY but it is down by 9% QoQ
The P/S is 35% above the last 4 quarters average of 1.3
Efficiency
How efficient is Plus Therapeutics business performance
The return on sales has surged by 73% year-on-year and by 9% since the previous quarter
The ROA has contracted by 43% YoY and by 20% from the previous quarter
Dividends
What is PSTV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PSTV.
Financial health
How did Plus Therapeutics financials performed over time
Plus Therapeutics's total assets is 40% lower than its total liabilities
Plus Therapeutics's total assets has surged by 99% QoQ but it has decreased by 21% YoY
PSTV's total liabilities has surged by 80% since the previous quarter and by 63% year-on-year
PSTV's debt is 145% greater than its equity
The debt to equity has dropped by 124% year-on-year but it has increased by 42% since the previous quarter
The equity has dropped by 58% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.